```
=> File .Biotech
=> s (subcalcaneal fat pads or heel pads or fat pads)
L1         5800 (SUBCALCANEAL FAT PADS OR HEEL PADS OR FAT PADS)

=> s l1 and (damag? or degenerat? or atroph?)
L2          551 L1 AND (DAMAG? OR DEGENERAT? OR ATROPH?)

=> s l2 and (treat? or therapeut? or ameliorat? or prevent?)
L3          472 L2 AND (TREAT? OR THERAPEUT? OR AMELIORAT? OR PREVENT?)

=> s l3 and (fat? acid or saturat? or unsaturat?)
L4          314 L3 AND (FAT? ACID OR SATURAT? OR UNSATURAT?)

=> s l4 and (palmitate or streate or myristate)
L5           13 L4 AND (PALMITATE OR STREATE OR MYRISTATE)

=> s l4 and (palmitoleate or oleate or vaccenate or linoleate)
L6           65 L4 AND (PALMITOLEATE OR OLEATE OR VACCENATE OR LINOLEATE)

=> s l5 and l6
L7            8 L5 AND L6

=> s l7 and (solut? or solid? or gel?)
L8            8 L7 AND (SOLUT? OR SOLID? OR GEL?)

=> dup rem l8
PROCESSING COMPLETED FOR L8
L9            7 DUP REM L8 (1 DUPLICATE REMOVED)

=> d l9 1-7 bib ab

L9   ANSWER 1 OF 7  USPATFULL on STN
AN     2003:165954  USPATFULL
TI     Novel assay
IN     Wise, Alan, Stevenage, UNITED KINGDOM
       Brown, Andrew James, Stevenage, UNITED KINGDOM
PI     US 2003113810      A1   20030619
AI     US 2002-203539     A1   20021008 (10)
       WO 2001-GB684           20010219
PRAI   GB 2000-3900       20000218
       GB 2000-7015       20000322
DT     Utility
FS     APPLICATION
LREP   DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE
       MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398
CLMN   Number of Claims: 18
ECL    Exemplary Claim: 1
DRWN   7 Drawing Page(s)
LN.CNT 1628
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     This invention relates to a method for identification of an agent that
       modulates activity of G-protein coupled receptor 41 (GPR 41), or
       G-protein coupled receptor 42 (GPR 42) which method comprises: (i)
       contacting a test agent with GPR 41, GPR42 or a variant of either
       thereof which is capable of coupling to a G-protein; and (ii) monitoring
       for GPR 41 or GPR 42 activity in the presence of a G-protein; thereby
       determining whether the test agent modulates GPR 41 or GPR 42 activity.
       An agent identifiable by this method is provided for use in the
       treatment of dyslipidaemia, coronary heart disease,
       atheroselerosis, thrombosis or obesity, angina, chronic renal failure,
       peripheral vascular disease, stroke, type II diabetes or metabolic
       syndrome (syndrome X).

L9   ANSWER 2 OF 7  USPATFULL on STN
AN     2003:30899  USPATFULL
```

TI Antisense oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression
IN Baker, Brenda F., Carlsbad, CA, UNITED STATES
Bennett, C. Frank, Carlsbad, CA, UNITED STATES
Butler, Madeline M., Rancho Sante Fe, CA, UNITED STATES
Shanahan, William R., JR., Sugar land, TX, UNITED STATES
PI US 2003022848 A1 20030130
AI US 2001-824322 A1 20010402 (9)
RLI Continuation-in-part of Ser. No. US 1999-313932, filed on 18 May 1999, PATENTED Continuation-in-part of Ser. No. US 1998-166186, filed on 5 Oct 1998, PATENTED
DT Utility
FS APPLICATION
LREP LICATLA & TYRRELL P.C., 66 E. MAIN STREET, MARLTON, NJ, 08053
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 6665
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-α (TNF-α). Antisense oligonucleotides targeted to nucleic acids encoding TNF-α_ are preferred. Methods of using these oligonucleotides for inhibition of TNF-α expression and for **treatment** of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TNF-α are provided.

L9 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
AN 2002:391493 CAPLUS
DN 136:391071
TI A method for restoring a fat-pad using a mixture of fatty acids
IN Desrosiers, Eric Andre
PA Bio Syntech Canada Inc., Can.
SO PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002039977	A2	20020523	WO 2001-CA1586	20011114
WO 2002039977	A3	20021031		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002094959	A1	20020718	US 2001-55493	20011029
AU 2002018081	A5	20020527	AU 2002-18081	20011114
EP 1339393	A2	20030903	EP 2001-996361	20011114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRAI US 2000-248228P P 20001115
US 2000-248570P P 20001116
US 2001-55493 A 20011029
WO 2001-CA1586 W 20011114

AB The present invention relates to a method for **treating damaged** or **degenerated fat pads** in a foot of a host in need thereof. The method comprises the step of injecting into the fat pad of the host a biocompatible solution having physicochem. and mech. properties substantially similar to a **fatty acid** mixture normally present in a healthy fat pad. For example,

fatty acids, **myristate** 1.9%, **palmitate** 15.9%, stearate 1.7%, **palmitoleate** 12.3%, **vaccenate** 4.8%, **oleate** 46.4% and **linoleate** 17.0% (weight/weight) were combined in an amber glass bottle, warmed to 65°, and mixed using a magnetic stir plate. The mixture was sterilized by filtration and dispensed in aseptic conditions, by 5 mL aliquots, in amber glass vials, to avoid photooxidn. Each vial, stored at or below room temperature, can be used by first warming it up slightly above the m.p. of the mixture (37-40°). The liquified solution is then drawn from the vial with a syringe fitted with a fine needle (26G). The plantar surface of the patient's foot is washed with soap, rinsed with water, dried, and prepared with 70% iso-Pr alc. and a sterile gauze wipe. The site of injection can first be anesthetized, and then injected within the **atrophic** fat pad, at about 1 cm below the surface of the skin. For the heel site, this injection site is directly above the calcaneus, where heel spur normally develops. The clinician can feel the increased resistance in the syringe as the fat pad becomes refilled.

L9 ANSWER 4 OF 7 USPATFULL on STN
AN 2002:273335 USPATFULL
TI Agouti polynucleotide compositions and methods of use
IN Woychik, Richard P., Orinda, CA, UNITED STATES
Bultman, Scott J., Lakewood, OH, UNITED STATES
Michaud, Edward J., UNITED STATES
PI US 2002151463 A1 20021017
US 6514747 B2 20030204
AI US 2001-781811 A1 20010212 (9)
RLI Division of Ser. No. US 1998-34088, filed on 3 Mar 1998, GRANTED, Pat. No. US 6310034 Continuation-in-part of Ser. No. US 1993-64385, filed on 21 May 1993, ABANDONED
DT Utility
FS APPLICATION
LREP GREGORY A. NELSON, AKERMAN, SENTERFITT AND EIDSON, P.A., 222 LAKEVIEW AVENUE, SUITE 400, P.O.BOX 3188, WEST PALM BEACH, FL, 33402-3188
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN 41 Drawing Page(s)
LN.CNT 11146
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods and compositions comprising novel agouti polypeptides and the polynucleotides which encode them. Also disclosed are DNA segments encoding these proteins derived from human and murine cell lines, and the use of these polynucleotides and polypeptides in a variety of diagnostic and **therapeutic** applications. Methods, compositions, kits, and devices are also provided for identifying compounds which are inhibitors of agouti activity, and for altering **fatty acid** synthetase activity and intracellular calcium levels in transformed cells.

L9 ANSWER 5 OF 7 USPATFULL on STN
AN 2002:179169 USPATFULL
TI Method for restoring a fat-pad
IN DesRosiers, Eric Andre, Outremont, CANADA
PI US 2002094959 A1 20020718
AI US 2001-55493 A1 20011029 (10)
PRAI US 2000-248228P 20001115 (60)
US 2000-248570P 20001116 (60)
DT Utility
FS APPLICATION
LREP David S. Resnick, NIXON PEABODY LLP, 101 Federal Street, Boston, MA, 02110
CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 550

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for **treating** **damaged** or **degenerated fat pads** in a foot of a host in need thereof. The method comprises the step of injecting into the fat pad of the host a biocompatiable **solution** having physico-chemical and mechanical properties substantially similar to a **fatty acid** mixture normally present in a healthy fat pad.

L9 ANSWER 6 OF 7 USPATFULL on STN
AN 2001:191105 USPATFULL
TI Agouti polypeptide compositions
IN Woychik, Richard P., Orinda, CA, United States
Bultman, Scott J., Lakewood, OH, United States
Michaud, Edward J., Kingston, TN, United States
PA UT-Battelle, LLC, Oak Ridge, TN, United States (U.S. corporation)
PI US 6310034 B1 20011030
AI US 1998-34088 19980303 (9)
RLI Continuation-in-part of Ser. No. US 1993-64385, filed on 21 May 1993, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Kammerer, Elyabik C.
LREP Williams, Morgan & Amerson
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 83 Drawing Figure(s); 41 Drawing Page(s)
LN.CNT 10935
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods and compositions comprising novel agouti polypeptides and the polynucleotides which encode them. Also disclosed are DNA segments encoding these proteins derived from human and murine cell lines, and the use of these polynucleotides and polypeptides in a variety of diagnostic and **therapeutic** applications. Methods, compositions, kits, and devices are also provided for identifying compounds which are inhibitors of agouti activity, and for altering **fatty acid** synthetase activity and intracellular calcium levels in transformed cells.

L9 ANSWER 7 OF 7 USPATFULL on STN
AN 93:24727 USPATFULL
TI Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using
IN Brillhart, Donald D., Cleveland, OH, United States
Maurer, Gerald L., Cincinnati, OH, United States
PA Lipotech Partners Limited Partnership, Cleveland, OH, United States (U.S. corporation)
PI US 5198250 19930330
AI US 1990-552588 19900716 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Penland, R. B.
LREP Wood, Herron & Evans
CLMN Number of Claims: 41
ECL Exemplary Claim: 21
DRWN No Drawings
LN.CNT 1647
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Food and pharmaceutical compositions are disclosed which contain amounts of short chain monounsaturated fatty acids or their derivatives sufficient to increase the content of the fatty acids within the tissues when said compositions are administered and to substantially improve the metabolic processing of lipids within animals.

```
=> dup rem l5
PROCESSING COMPLETED FOR L5
L10          12 DUP REM L5 (1 DUPLICATE REMOVED)

=> d l10 1-12 bib ab

L10  ANSWER 1 OF 12  USPATFULL on STN
AN     2004:51519  USPATFULL
TI     Pharmaceutical composition for treating IL-1 related diseases
       or disorders
IN     Seong, Sang-Cheol, Seoul, KOREA, REPUBLIC OF
       Lee, Myung-Chul, Seoul, KOREA, REPUBLIC OF
       Jo, Hyun-Chul, Seoul, KOREA, REPUBLIC OF
       Park, Jung-Sun, Seoul, KOREA, REPUBLIC OF
       Jeong, Mi-Young, Seoul, KOREA, REPUBLIC OF
PI     US 2004038950      A1   20040226
AI     US 2003-358249     A1   20030205 (10)
PRAI   KR 2002-50568       20020826
DT     Utility
FS     APPLICATION
LREP   NIXON & VANDERHYE, PC, 1100 N GLEBE ROAD, 8TH FLOOR, ARLINGTON, VA,
       22201-4714
CLMN   Number of Claims: 18
ECL    Exemplary Claim: 1
DRWN   21 Drawing Page(s)
LN.CNT 867
AB     The present invention relates to a pharmaceutical composition for
       treating (IL-1)-related disease or disorder, which comprises:
       (a) a therapeutically effective dose of dehyroepiandrosterone
       or its derivative represented by the formula (I); and (b) a
       pharmaceutically acceptable carrier:   ##STR1##

       wherein X is H,   ##STR2##

        R.sub.1 is H or --NH.sub.2; R.sub.2 is H, --COOH, --NH.sub.2 or
       ##STR3##

        Ar is unsubstituted or substituted phenyl; and n is an integer of 1-20.

L10  ANSWER 2 OF 12  USPATFULL on STN
AN     2004:31247  USPATFULL
TI     Modulation of nitric oxide synthase by PKC
IN     King, George L., Dover, MA, UNITED STATES
PA     Joslin Diabetes Center, Inc., a Massachusetts corporation (U.S.
       corporation)
PI     US 2004023386      A1   20040205
AI     US 2003-629928     A1   20030729 (10)
RLI    Continuation of Ser. No. US 2001-907012, filed on 17 Jul 2001, ABANDONED
PRAI   US 2000-219246P     20000718 (60)
DT     Utility
FS     APPLICATION
LREP   FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110
CLMN   Number of Claims: 26
ECL    Exemplary Claim: 1
DRWN   No Drawings
LN.CNT 1637
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB     Featured are methods of modulating endothelial NOS (eNOS) expression,
       e.g., insulin-stimulated eNOS expression, by modulating PKCβ. The
       methods are useful in the treatment of insulin-related
       disorders, e.g., hypertension.

L10  ANSWER 3 OF 12  USPATFULL on STN
AN     2003:165954  USPATFULL
TI     Novel assay
```

IN Wise, Alan, Stevenage, UNITED KINGDOM
Brown, Andrew James, Stevenage, UNITED KINGDOM
PI US 2003113810 A1 20030619
AI US 2002-203539 A1 20021008 (10)
WO 2001-GB684 20010219
PRAI GB 2000-3900 20000218
GB 2000-7015 20000322
DT Utility
FS APPLICATION
LREP DAVID J LEVY, CORPORATE INTELLECTUAL PROPERTY, GLAXOSMITHKLINE, FIVE MOORE DR., PO BOX 13398, RESEARCH TRIANGLE PARK, NC, 27709-3398
CLMN Number of Claims: 18
ECL Exemplary Claim: 1
DRWN 7 Drawing Page(s)
LN.CNT 1628
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to a method for identification of an agent that modulates activity of G-protein coupled receptor 41 (GPR 41), or G-protein coupled receptor 42 (GPR 42) which method comprises: (i) contacting a test agent with GPR 41, GPR42 or a variant of either thereof which is capable of coupling to a G-protein; and (ii) monitoring for GPR 41 or GPR 42 activity in the presence of a G-protein; thereby determining whether the test agent modulates GPR 41 or GPR 42 activity. An agent identifiable by this method is provided for use in the **treatment** of dyslipidaemia, coronary heart disease, atheroselerosis, thrombosis or obesity, angina, chronic renal failure, peripheral vascular disease, stroke, type II diabetes or metabolic syndrome (syndrome X).

L10 ANSWER 4 OF 12 USPATFULL on STN
AN 2003:30899 USPATFULL
TI Antisense oligonucleotide modulation of tumor necrosis factor-alpha (TNF-alpha) expression
IN Baker, Brenda F., Carlsbad, CA, UNITED STATES
Bennett, C. Frank, Carlsbad, CA, UNITED STATES
Butler, Madeline M., Rancho Sante Fe, CA, UNITED STATES
Shanahan, William R., JR., Sugar land, TX, UNITED STATES
PI US 2003022848 A1 20030130
AI US 2001-824322 A1 20010402 (9)
RLI Continuation-in-part of Ser. No. US 1999-313932, filed on 18 May 1999, PATENTED Continuation-in-part of Ser. No. US 1998-166186, filed on 5 Oct 1998, PATENTED
DT Utility
FS APPLICATION
LREP LICATLA & TYRRELL P.C., 66 E. MAIN STREET, MARLTON, NJ, 08053
CLMN Number of Claims: 11
ECL Exemplary Claim: 1
DRWN 10 Drawing Page(s)
LN.CNT 6665
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods are provided for inhibiting the expression of human tumor necrosis factor-α (TNF-α). Antisense oligonucleotides targeted to nucleic acids encoding TNF-α are preferred. Methods of using these oligonucleotides for inhibition of TNF-α expression and for **treatment** of diseases, particularly inflammatory and autoimmune diseases, associated with overexpression of TNF-α are provided.

L10 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1
AN 2002:391493 CAPLUS
DN 136:391071
TI A method for restoring a fat-pad using a mixture of fatty acids
IN Desrosiers, Eric Andre
PA Bio Syntech Canada Inc., Can.
SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002039977	A2	20020523	WO 2001-CA1586	20011114
	WO 2002039977	A3	20021031		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002094959	A1	20020718	US 2001-55493	20011029
	AU 2002018081	A5	20020527	AU 2002-18081	20011114
	EP 1339393	A2	20030903	EP 2001-996361	20011114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2000-248228P	P	20001115		
	US 2000-248570P	P	20001116		
	US 2001-55493	A	20011029		
	WO 2001-CA1586	W	20011114		

AB The present invention relates to a method for **treating damaged** or **degenerated fat pads** in a foot of a host in need thereof. The method comprises the step of injecting into the fat pad of the host a biocompatible solution having physicochem. and mech. properties substantially similar to a **fatty acid** mixture normally present in a healthy fat pad. For example, fatty acids, **myristate** 1.9%, **palmitate** 15.9%, stearate 1.7%, palmitoleate 12.3%, vaccenate 4.8%, oleate 46.4% and linoleate 17.0% (weight/weight) were combined in an amber glass bottle, warmed to 65°, and mixed using a magnetic stir plate. The mixture was sterilized by filtration and dispensed in aseptic conditions, by 5 mL aliquots, in amber glass vials, to avoid photooxidn. Each vial, stored at or below room temperature, can be used by first warming it up slightly above the m.p. of the mixture (37-40°). The liquified solution is then drawn from the vial with a syringe fitted with a fine needle (26G). The plantar surface of the patient's foot is washed with soap, rinsed with water, dried, and prepared with 70% iso-Pr alc. and a sterile gauze wipe. The site of injection can first be anesthetized, and then injected within the **atrophic** fat pad, at about 1 cm below the surface of the skin. For the heel site, this injection site is directly above the calcaneus, where heel spur normally develops. The clinician can feel the increased resistance in the syringe as the fat pad becomes refilled.

L10 ANSWER 6 OF 12 USPATFULL on STN
AN 2002:273335 USPATFULL
TI Agouti polynucleotide compositions and methods of use
IN Woychik, Richard P., Orinda, CA, UNITED STATES
Bultman, Scott J., Lakewood, OH, UNITED STATES
Michaud, Edward J., UNITED STATES

PI	US 2002151463	A1	20021017
	US 6514747	B2	20030204
AI	US 2001-781811	A1	20010212 (9)

RLI Division of Ser. No. US 1998-34088, filed on 3 Mar 1998, GRANTED, Pat. No. US 6310034 Continuation-in-part of Ser. No. US 1993-64385, filed on 21 May 1993, ABANDONED
DT Utility
FS APPLICATION
LREP GREGORY A. NELSON, AKERMAN, SENTERFITT AND EIDSON, P.A., 222 LAKEVIEW AVENUE, SUITE 400, P.O.BOX 3188, WEST PALM BEACH, FL, 33402-3188
CLMN Number of Claims: 50

ECL Exemplary Claim: 1
DRWN 41 Drawing Page(s)
LN.CNT 11146
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods and compositions comprising novel agouti polypeptides and the polynucleotides which encode them. Also disclosed are DNA segments encoding these proteins derived from human and murine cell lines, and the use of these polynucleotides and polypeptides in a variety of diagnostic and **therapeutic** applications. Methods, compositions, kits, and devices are also provided for identifying compounds which are inhibitors of agouti activity, and for altering **fatty acid** synthetase activity and intracellular calcium levels in transformed cells.

L10 ANSWER 7 OF 12 USPATFULL on STN
AN 2002:207547 USPATFULL
TI Acetyl-coenzyme a carboxylase 2 as a target in the regulation of fat burning, fat accumulation, energy homeostasis and insulin action
IN Wakil, Salih J., Houston, TX, UNITED STATES
Matzuk, Martin, Pearland, TX, UNITED STATES
Abu-Elheiga, Lutfi, Houston, TX, UNITED STATES
PI US 2002112253 A1 20020815
AI US 2001-929575 A1 20010814 (9)
RLI Continuation-in-part of Ser. No. US 2000-749109, filed on 26 Dec 2000, PENDING
DT Utility
FS APPLICATION
LREP Benjamin Aaron Adler, ADLER & ASSOCIATES, 8011 Candle Lane, Houston, TX, 77071
CLMN Number of Claims: 23
ECL Exemplary Claim: 1
DRWN 6 Drawing Page(s)
LN.CNT 949
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention highlights the role of acetyl-CoA carboxylase through its product malonyl-CoA in regulating **fatty acid** oxidation and synthesis, glucose metabolism and energy homeostasis. It discloses transgenic mice with inactivating mutations in the endogenous gene for the acetyl-CoA carboxylase 2 isoform of acetyl-CoA carboxylase. Inactivation of acetyl-CoA carboxylase 2 results in mice exhibiting a phenotype of reduced malonyl-CoA levels in skeletal muscle and heart, unrestricted fat oxidation, and reduced fat accumulation in the liver and fat storage cells. As a result, the mice consume more food but accumulate less fat and remain leaner than wild-type mice fed the same diet. These results demonstrate that inhibition of ACC2 acetyl-CoA carboxylase could be used to regulate fat oxidation and accumulation for purposes of weight control. The instant invention provides a useful animal model to regulate malonyl-CoA production by ACC2 in the regulation of **fatty acid** oxidation by muscle, heart, liver and other tissues. They also identify potential inhibitors for studying the mechanisms of fat metabolism and weight control.

L10 ANSWER 8 OF 12 USPATFULL on STN
AN 2002:179169 USPATFULL
TI Method for restoring a fat-pad
IN DesRosiers, Eric Andre, Outremont, CANADA
PI US 2002094959 A1 20020718
AI US 2001-55493 A1 20011029 (10)
PRAI US 2000-248228P 20001115 (60)
US 2000-248570P 20001116 (60)
DT Utility
FS APPLICATION
LREP David S. Resnick, NIXON PEABODY LLP, 101 Federal Street, Boston, MA, 02110

CLMN Number of Claims: 36
ECL Exemplary Claim: 1
DRWN 2 Drawing Page(s)
LN.CNT 550
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a method for **treating damaged** or **degenerated fat pads** in a foot of a host in need thereof. The method comprises the step of injecting into the fat pad of the host a biocompatiable solution having physico-chemical and mechanical properties substantially similar to a **fatty acid** mixture normally present in a healthy fat pad.

L10 ANSWER 9 OF 12 USPATFULL on STN
AN 2002:92064 USPATFULL
TI Modulation of nitric oxide synthase by PKC
IN King, George L., Dover, MA, UNITED STATES
PI US 2002048581 A1 20020425
AI US 2001-907012 A1 20010717 (9)
PRAI US 2000-219246P 20000718 (60)
DT Utility
FS APPLICATION
LREP LOUIS MYERS, Fish & Richardson P.C., 225 Franklin Street, Boston, MA, 02110-2804
CLMN Number of Claims: 26
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1637
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Featured are methods of modulating endothelial NOS (eNOS) expression, e.g., insulin-stimulated eNOS expression, by modulating PKCβ. The methods are useful in the **treatment** of insulin-related disorders, e.g., hypertension.

L10 ANSWER 10 OF 12 USPATFULL on STN
AN 2001:191105 USPATFULL
TI Agouti polypeptide compositions
IN Woychik, Richard P., Orinda, CA, United States
Bultman, Scott J., Lakewood, OH, United States
Michaud, Edward J., Kingston, TN, United States
PA UT-Battelle, LLC, Oak Ridge, TN, United States (U.S. corporation)
PI US 6310034 B1 20011030
AI US 1998-34088 19980303 (9)
RLI Continuation-in-part of Ser. No. US 1993-64385, filed on 21 May 1993, now abandoned
DT Utility
FS GRANTED
EXNAM Primary Examiner: Kammerer, Elyabik C.
LREP Williams, Morgan & Amerson
CLMN Number of Claims: 34
ECL Exemplary Claim: 1
DRWN 83 Drawing Figure(s); 41 Drawing Page(s)
LN.CNT 10935
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Disclosed are methods and compositions comprising novel agouti polypeptides and the polynucleotides which encode them. Also disclosed are DNA segments encoding these proteins derived from human and murine cell lines, and the use of these polynucleotides and polypeptides in a variety of diagnostic and **therapeutic** applications. Methods, compositions, kits, and devices are also provided for identifying compounds which are inhibitors of agouti activity, and for altering **fatty acid** synthetase activity and intracellular calcium levels in transformed cells.

L10 ANSWER 11 OF 12 USPATFULL on STN

AN 93:24727 USPATFULL
TI Food and pharmaceutical compositions containing short chain monounsaturated fatty acids and methods of using
IN Brillhart, Donald D., Cleveland, OH, United States
Maurer, Gerald L., Cincinnati, OH, United States
PA Lipotech Partners Limited Partnership, Cleveland, OH, United States (U.S. corporation)
PI US 5198250 19930330
AI US 1990-552588 19900716 (7)
DT Utility
FS Granted
EXNAM Primary Examiner: Penland, R. B.
LREP Wood, Herron & Evans
CLMN Number of Claims: 41
ECL Exemplary Claim: 21
DRWN No Drawings
LN.CNT 1647
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Food and pharmaceutical compositions are disclosed which contain amounts of short chain monounsaturated fatty acids or their derivatives sufficient to increase the content of the fatty acids within the tissues when said compositions are administered and to substantially improve the metabolic processing of lipids within animals.

L10 ANSWER 12 OF 12 USPATFULL on STN
AN 81:8142 USPATFULL
TI Novel 15-deoxy-16-ethynyl and -16-(1-propynyl)-1-carboxy and 1-carbinol prostaglandins of the A, D, E and F series
IN Floyd, Jr., Middleton B., Suffern, NY, United States
Weiss, Martin J., Oradell, NJ, United States
Grudzinskas, Charles V., Nyack, NY, United States
Chen, Sow-Mei L., Park Ridge, NJ, United States
PA American Cyanamid Company, Stamford, CT, United States (U.S. corporation)
PI US 4250325 19810210
AI US 1978-969479 19781214 (5)
RLI Continuation-in-part of Ser. No. US 1977-857848, filed on 5 Dec 1977, now patented, Pat. No. US 4190596 Ser. No. Ser. No. US 1977-857849, filed on 5 Dec 1977, now patented, Pat. No. US 4190597 And Ser. No. US 1977-857714, filed on 5 Dec 1977, now patented, Pat. No. US 4191699 , each which is a continuation-in-part of Ser. No. US 1976-706343, filed on 19 Jul 1976, now patented, Pat. No. US 4061670
DT Utility
FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Hammond, Richard J.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1996
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention described herein relates to novel 15-deoxy-16-hydroxy-16-ethynyl or 16-(1-propynyl) prostaglandins of E, F, D and A series having on the terminal methylene carbon of the alpha chain a substituent selected from the group consisting of: ##STR1## wherein R.sub.1 is selected from the group consisting of hydrogen and C.sub.1 -C.sub.6 alkyl; R.sub.15 is selected from the group consisting of C.sub.1 -C.sub.4 alkyl, di-C.sub.1 -C.sub.4 -alkylamino, phenyl and phenyl substituted with one or more substituents selected from the group consisting of C.sub.1 -C.sub.4 alkyl, OR, SR, F or Cl, wherein R is an alkyl group.

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

STN INTERNATIONAL LOGOFF AT 15:12:17 ON 06 MAR 2004